Name: BIM-IOL System in Open-angle glaucoma or ocular hypertension: Indication
Published: 2026-09-17T18:17:42-04:00

Product information and disease description Product description Product information

Indication

2 evidence topics · 3 sources

Proposed use under investigation

“SpyGlass Pharma’s lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary non-bioerodible drug pads attached to its intraocular lens, was designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).” (opens the source at this quote in a new tab)

Population studied in the phase 3 trials

“Each prospective, multicenter, randomized, masked, controlled Phase 3 clinical trial evaluates the safety and efficacy of the BIM-IOL System (78 mcg) in patients with OAG or OHT and a concomitant cataract, who are taking up to two IOP-lowering medications.” (opens the source at this quote in a new tab)

“Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension” (opens the source at this quote in a new tab)
“Planned removal of cataract” (opens the source at this quote in a new tab)

Approved indication

Not applicable.